Weiner, Michael W.Veitch, Dallas P.Aisen, Paul S.Beckett, Laurel A.Cairns, Nigel J.Green, Robert C.Harvey, DanielleJack, Clifford R., Jr.Jagust, WilliamMorris, John C.Petersen, Ronald C.Salazar, JenniferSaykin, Andrew J.Shaw, Leslie M.Toga, Arthur W.Trojanowski, John Q.2018-10-122018-10-122017-05Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., … Trojanowski, J. Q. (2017). The Alzheimer’s Disease Neuroimaging Initiative 3: continued innovation for clinical trial improvement. Alzheimer’s & Dementia : The Journal of the Alzheimer’s Association, 13(5), 561–571. http://doi.org/10.1016/j.jalz.2016.10.006https://hdl.handle.net/1805/17540INTRODUCTION: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. METHODS: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. RESULTS: Multimodal analyses will provide insight into AD pathophysiology and disease progression. DISCUSSION: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.en-USPublisher PolicyAlzheimer's diseaseAmyloid phenotypingBrain Health RegistryCentiloid methodClinical trial biomarkersFunctional connectivityTau imagingArticle